Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South St, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Clin Rheumatol. 2018 May;37(5):1229-1237. doi: 10.1007/s10067-018-4024-3. Epub 2018 Feb 9.
A variety of autoantibodies has been involved in the pathogenesis of systemic lupus erythematosus (SLE), some of which are well known and applied as disease biomarkers. This study aimed to determine the prevalence of a novel autoantibody, anti-tubulin-α-1C, in patients with SLE and investigate its clinical significance. Anti-tubulin-α-1C autoantibody levels were determined by enzyme-linked immunosorbent assay (ELISA) in 128 SLE patients, 38 primary Sjögren's syndrome (pSS) patients, and 106 healthy controls (HCs).White blood cell (WBC) count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IgM, IgG, C3, C4, RF, ANA, dsDNA, Sm, AnuA, aCL, anti-SSA, and anti-SSB were measured by standard laboratory techniques. SLE Disease Activity Index (SLEDAI) was evaluated accordingly. Anti-tubulin-α-1C antibody levels were significantly increased in SLE patients. Elevated anti-tubulin-α-1C were correlated with higher levels of SLEDAI, increased titers of anti-Sm antibody, and decreased titers of anti-dsDNA antibody and significantly associated with cutaneous and mucosal vasculitis and milder renal involvement. Anti-tubulin-α-1C may become a novel biomarker indicative of active vasculitis in SLE and could be applied in future clinical practice.
多种自身抗体参与了系统性红斑狼疮（SLE）的发病机制，其中一些已被广泛了解并作为疾病生物标志物应用。本研究旨在确定新型自身抗体抗微管蛋白-α-1C 在 SLE 患者中的流行情况，并探讨其临床意义。通过酶联免疫吸附试验（ELISA）检测了 128 例 SLE 患者、38 例原发性干燥综合征（pSS）患者和 106 名健康对照者（HCs）的抗微管蛋白-α-1C 自身抗体水平。采用标准实验室技术检测白细胞（WBC）计数、红细胞沉降率（ESR）、C 反应蛋白（CRP）、IgM、IgG、C3、C4、RF、ANA、dsDNA、Sm、AnuA、aCL、抗 SSA 和抗 SSB。根据 SLE 疾病活动指数（SLEDAI）进行评估。SLE 患者的抗微管蛋白-α-1C 抗体水平显著升高。升高的抗微管蛋白-α-1C 与 SLEDAI 水平升高、抗 Sm 抗体滴度升高以及抗 dsDNA 抗体滴度降低相关，且与皮肤和黏膜血管炎及较轻的肾脏受累显著相关。抗微管蛋白-α-1C 可能成为反映 SLE 活动性血管炎的新型生物标志物，并可应用于未来的临床实践。
